0001193125-23-002398.txt : 20230105 0001193125-23-002398.hdr.sgml : 20230105 20230105161304 ACCESSION NUMBER: 0001193125-23-002398 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20221230 ITEM INFORMATION: Entry into a Material Definitive Agreement FILED AS OF DATE: 20230105 DATE AS OF CHANGE: 20230105 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CytomX Therapeutics, Inc. CENTRAL INDEX KEY: 0001501989 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 273521219 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37587 FILM NUMBER: 23511432 BUSINESS ADDRESS: STREET 1: 151 OYSTER POINT BLVD. STREET 2: SUITE 400 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650.515.3185 MAIL ADDRESS: STREET 1: 151 OYSTER POINT BLVD. STREET 2: SUITE 400 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 8-K 1 d405031d8k.htm 8-K 8-K
false 0001501989 0001501989 2022-12-30 2022-12-30

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 30, 2022

 

 

CYTOMX THERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-37587   27-3521219

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

151 Oyster Point Blvd.

Suite 400

South San Francisco, CA

     94080
(Address of Principal Executive Offices)     (Zip Code)

Registrant’s telephone number, including area code: (650) 515-3185

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.00001 par value per share   CTMX   Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 1.01

Entry into a Material Definitive Agreement.

On December 30, 2022, CytomX Therapeutics, Inc. (the “Company”) entered into a Collaboration and License Agreement (the “Collaboration and License Agreement”) with ModernaTX, Inc., a wholly-owned subsidiary of Moderna, Inc. (“Moderna”), pursuant to which the Company and Moderna will collaborate on the creation of mRNA-based conditionally-activated investigational therapies utilizing the Company’s Probody® therapeutic platform and Moderna’s mRNA and lipid nanoparticle technologies. The collaboration will leverage core scientific advances at Moderna and the Company to open up the strategy of encoding potent, masked biologics through mRNA technologies, for the potential treatment of oncology and non-oncology conditions. The Company and Moderna will collaborate on a specified number of preclinical research and discovery programs (“Collaboration Programs”) within a specified period under the Collaboration and License Agreement.

Under the Collaboration and License Agreement, the Company granted Moderna an exclusive, worldwide, royalty-bearing license under certain Company intellectual property to develop, manufacture, commercialize and otherwise exploit licensed products (“Licensed Products”) for all human and non-human diagnostic, prophylactic and therapeutic uses, subject to certain exceptions with respect to Licensed Products within certain Collaboration Programs, and a non-exclusive, worldwide, royalty-free license under certain Company intellectual property to conduct pre-clinical research in accordance with work plans under the Collaboration and License Agreement. Moderna granted the Company a non-exclusive, worldwide, royalty-free license under certain intellectual property of Moderna to conduct preclinical research and discovery in accordance with work plans under the Collaboration and License Agreement. Each party has the right to sublicense its rights under the Collaboration and License Agreement subject to certain conditions.

Under the terms of the Collaboration and License Agreement, Moderna will make an upfront cash payment to the Company of $35 million, including $5 million of pre-paid research funding. The Company will be eligible to receive future development, regulatory and commercial milestone payments of up to $1.2 billion. Moderna will pay the Company tiered royalties on global net sales of Licensed Products from high single digit to low-teen percentages, subject to certain reductions. Moderna’s royalty obligations continue with respect to each country and each Product until the later of (i) the date on which such Licensed Product is no longer covered by certain patent rights, (ii) the 10th anniversary of the first commercial sale of such product in such country, and (iii) the loss of regulatory exclusivity for such Licensed Product in such country.

The Collaboration and License Agreement also provides Moderna with a one-time option to participate in a future equity financing by the Company subject to certain terms, conditions and regulatory requirements.

The Collaboration and License Agreement will continue in effect on a Licensed Product-by-Licensed Product and country-by-country basis until the expiration of the obligation to make payments under the Collaboration and License Agreement with respect to such Licensed Product in each country, unless earlier terminated by either party pursuant to its terms. Either the Company or Moderna may terminate the Collaboration and License Agreement for the other party’s insolvency or certain uncured breaches or if the other party or any of its sublicensees or affiliates challenge certain patents of such party and such challenge is not rescinded within sixty (60) days. In addition, Moderna may terminate the Collaboration and License Agreement on a Licensed Product-by-Licensed Product or Collaboration Program-by-Collaboration Program basis effective immediately upon written notice to the Company if Moderna believes in good faith that it is not advisable to continue to develop or commercialize any Licensed Product in such Collaboration Program as a result of a perceived serious safety issue. Moderna also may terminate the Collaboration and License Agreement in its entirety after the second anniversary of the effective date of the Collaboration and License Agreement subject to certain conditions within specified time periods in the Collaboration and License Agreement. Moderna also may terminate the Collaboration and License Agreement on a Licensed Product-by-Licensed Product basis at any time subject to certain conditions within specified time periods in the Collaboration and License Agreement.

The foregoing summary of the material terms and conditions of the Collaboration and License Agreement is qualified in its entirety by the full agreement, a copy of which will be filed as an exhibit to the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. The Company intends to omit certain confidential portions of the Collaboration and License Agreement.

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    CYTOMX THERAPEUTICS, INC.
Date: January 5, 2023     By:  

/s/ Lloyd Rowland

     

Lloyd Rowland

Senior Vice President, General Counsel

 EX-101.SCH 2 ctmx-20221230.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 ctmx-20221230_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, Address Line Three Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 4 ctmx-20221230_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Document and Entity Information
Dec. 30, 2022
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001501989
Document Type 8-K
Document Period End Date Dec. 30, 2022
Entity Registrant Name CYTOMX THERAPEUTICS, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-37587
Entity Tax Identification Number 27-3521219
Entity Address, Address Line One 151 Oyster Point
Entity Address, Address Line Two Blvd.
Entity Address, Address Line Three Suite 400
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code (650)
Local Phone Number 515-3185
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.00001 par value per share
Trading Symbol CTMX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 6 d405031d8k_htm.xml IDEA: XBRL DOCUMENT 0001501989 2022-12-30 2022-12-30 false 0001501989 8-K 2022-12-30 CYTOMX THERAPEUTICS, INC. DE 001-37587 27-3521219 151 Oyster Point Blvd. Suite 400 South San Francisco CA 94080 (650) 515-3185 false false false false Common Stock, $0.00001 par value per share CTMX NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://cytomx.com//20221230/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d405031d8k.htm ctmx-20221230.xsd ctmx-20221230_lab.xml ctmx-20221230_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d405031d8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "d405031d8k.htm" ] }, "labelLink": { "local": [ "ctmx-20221230_lab.xml" ] }, "presentationLink": { "local": [ "ctmx-20221230_pre.xml" ] }, "schema": { "local": [ "ctmx-20221230.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ctmx", "nsuri": "http://cytomx.com/20221230", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d405031d8k.htm", "contextRef": "duration_2022-12-30_to_2022-12-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://cytomx.com//20221230/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d405031d8k.htm", "contextRef": "duration_2022-12-30_to_2022-12-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytomx.com//20221230/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytomx.com//20221230/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytomx.com//20221230/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytomx.com//20221230/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytomx.com//20221230/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytomx.com//20221230/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three", "terseLabel": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytomx.com//20221230/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytomx.com//20221230/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytomx.com//20221230/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytomx.com//20221230/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytomx.com//20221230/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytomx.com//20221230/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytomx.com//20221230/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytomx.com//20221230/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytomx.com//20221230/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytomx.com//20221230/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytomx.com//20221230/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytomx.com//20221230/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytomx.com//20221230/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytomx.com//20221230/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytomx.com//20221230/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytomx.com//20221230/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytomx.com//20221230/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cytomx.com//20221230/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 13 0001193125-23-002398-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-002398-xbrl.zip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end